PROK Quote, Financials, Valuation and Earnings

CEL-SCI Corp. has a net margin of -16517.51% compared to ProKidney Corp.'s net margin of --. ProKidney Corp.'s return on equity of -42.51% beat CEL-SCI Corp.'s return on equity of -266.61%.

ProKidney Corp. has a consensus price target of $6.50, signalling upside risk potential of 156.92%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 802.34%. Given that CEL-SCI Corp. has higher upside potential than ProKidney Corp., analysts believe CEL-SCI Corp. is more attractive than ProKidney Corp..

ProKidney Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.

ProKidney Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProKidney Corp. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.

ProKidney Corp. quarterly revenues are $217K, which are larger than CEL-SCI Corp. quarterly revenues of --. ProKidney Corp.'s net income of -$35.8M is lower than CEL-SCI Corp.'s net income of -$5.7M. Notably, ProKidney Corp.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProKidney Corp. is 444.41x versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Erasca, Inc. has a net margin of -16517.51% compared to ProKidney Corp.'s net margin of --. ProKidney Corp.'s return on equity of -42.51% beat Erasca, Inc.'s return on equity of -32.03%.

ProKidney Corp. has a consensus price target of $6.50, signalling upside risk potential of 156.92%. On the other hand Erasca, Inc. has an analysts' consensus of $5.13 which suggests that it could grow by 47.27%. Given that ProKidney Corp. has higher upside potential than Erasca, Inc., analysts believe ProKidney Corp. is more attractive than Erasca, Inc..

ProKidney Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Erasca, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

ProKidney Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Erasca, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProKidney Corp. pays -- of its earnings as a dividend. Erasca, Inc. pays out -- of its earnings as a dividend.

ProKidney Corp. quarterly revenues are $217K, which are larger than Erasca, Inc. quarterly revenues of --. ProKidney Corp.'s net income of -$35.8M is lower than Erasca, Inc.'s net income of -$30.6M. Notably, ProKidney Corp.'s price-to-earnings ratio is -- while Erasca, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProKidney Corp. is 444.41x versus -- for Erasca, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma, Inc. has a net margin of -16517.51% compared to ProKidney Corp.'s net margin of -953.4%. ProKidney Corp.'s return on equity of -42.51% beat IGC Pharma, Inc.'s return on equity of -94.42%.

ProKidney Corp. has a consensus price target of $6.50, signalling upside risk potential of 156.92%. On the other hand IGC Pharma, Inc. has an analysts' consensus of $3.88 which suggests that it could grow by 1192.1%. Given that IGC Pharma, Inc. has higher upside potential than ProKidney Corp., analysts believe IGC Pharma, Inc. is more attractive than ProKidney Corp..

ProKidney Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison IGC Pharma, Inc. has a beta of 0.242, suggesting its less volatile than the S&P 500 by 75.839%.

ProKidney Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProKidney Corp. pays -- of its earnings as a dividend. IGC Pharma, Inc. pays out -- of its earnings as a dividend.

ProKidney Corp. quarterly revenues are $217K, which are larger than IGC Pharma, Inc. quarterly revenues of $191K. ProKidney Corp.'s net income of -$35.8M is lower than IGC Pharma, Inc.'s net income of -$1.8M. Notably, ProKidney Corp.'s price-to-earnings ratio is -- while IGC Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProKidney Corp. is 444.41x versus 22.51x for IGC Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Lineage Cell Therapeutics, Inc. has a net margin of -16517.51% compared to ProKidney Corp.'s net margin of -808.26%. ProKidney Corp.'s return on equity of -42.51% beat Lineage Cell Therapeutics, Inc.'s return on equity of -117.46%.

ProKidney Corp. has a consensus price target of $6.50, signalling upside risk potential of 156.92%. On the other hand Lineage Cell Therapeutics, Inc. has an analysts' consensus of $4.17 which suggests that it could grow by 152.53%. Given that ProKidney Corp. has higher upside potential than Lineage Cell Therapeutics, Inc., analysts believe ProKidney Corp. is more attractive than Lineage Cell Therapeutics, Inc..

ProKidney Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Lineage Cell Therapeutics, Inc. has a beta of 1.776, suggesting its more volatile than the S&P 500 by 77.601%.

ProKidney Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lineage Cell Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProKidney Corp. pays -- of its earnings as a dividend. Lineage Cell Therapeutics, Inc. pays out -- of its earnings as a dividend.

ProKidney Corp. quarterly revenues are $217K, which are smaller than Lineage Cell Therapeutics, Inc. quarterly revenues of $3.7M. ProKidney Corp.'s net income of -$35.8M is lower than Lineage Cell Therapeutics, Inc.'s net income of -$29.8M. Notably, ProKidney Corp.'s price-to-earnings ratio is -- while Lineage Cell Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProKidney Corp. is 444.41x versus 34.46x for Lineage Cell Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.